In an interview with Ed Silverman of Statnews, Dr. Gellad discusses the new Sarepta Therapeutics Drug for Duchenne Muscular Dystrophy, coming in at roughly $300,00 per year for patients.
In an interview with Ed Silverman of Statnews, Dr. Gellad discusses the new Sarepta Therapeutics Drug for Duchenne Muscular Dystrophy, coming in at roughly $300,00 per year for patients.